AR029875A1 - Derivados de 4-fenil-piridina - Google Patents

Derivados de 4-fenil-piridina

Info

Publication number
AR029875A1
AR029875A1 ARP010103499A ARP010103499A AR029875A1 AR 029875 A1 AR029875 A1 AR 029875A1 AR P010103499 A ARP010103499 A AR P010103499A AR P010103499 A ARP010103499 A AR P010103499A AR 029875 A1 AR029875 A1 AR 029875A1
Authority
AR
Argentina
Prior art keywords
pyridine
phenyl
derivatives
nrlc
receptor
Prior art date
Application number
ARP010103499A
Other languages
English (en)
Inventor
Torsten Hoffmann
Patrick Schnider
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR029875A1 publication Critical patent/AR029875A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

El nuevo invento se refiere a compuestos de las formulas generales (1) o (2), en donde Ra es un grupo de estructuras (3) o es -NH(CH2)2OH, -NRlC(O)CH3 o -NRlC(O)-ciclopropilo; R? es metilo o cloro; Rl es hidrogeno o metilo; R es hidrogeno o -(CH2)2OH; y n es 1 o 2 y sus sales de adicion de ácido farmacéuticamente aceptables. Estos compuestos tienen buena afinidad al receptor de NK-1 y por tanto pueden utilizarse en el tratamiento o prevencion de enfermedades relacionadas con este receptor.
ARP010103499A 2000-07-24 2001-07-23 Derivados de 4-fenil-piridina AR029875A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00115846 2000-07-24

Publications (1)

Publication Number Publication Date
AR029875A1 true AR029875A1 (es) 2003-07-16

Family

ID=8169331

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103499A AR029875A1 (es) 2000-07-24 2001-07-23 Derivados de 4-fenil-piridina

Country Status (38)

Country Link
US (2) US6576762B2 (es)
EP (1) EP1305319B1 (es)
JP (1) JP4118673B2 (es)
KR (1) KR100527214B1 (es)
CN (1) CN1192032C (es)
AR (1) AR029875A1 (es)
AT (1) ATE322496T1 (es)
AU (2) AU2001282005B2 (es)
BR (1) BR0112695A (es)
CA (1) CA2416874C (es)
CY (1) CY1106113T1 (es)
CZ (1) CZ2003528A3 (es)
DE (1) DE60118569T2 (es)
DK (1) DK1305319T3 (es)
EC (1) ECSP034446A (es)
ES (1) ES2260265T3 (es)
GT (1) GT200100148A (es)
HK (1) HK1058360A1 (es)
HR (1) HRP20030031A2 (es)
HU (1) HU229231B1 (es)
IL (2) IL153837A0 (es)
JO (1) JO2321B1 (es)
MA (1) MA26933A1 (es)
MX (1) MXPA03000367A (es)
MY (1) MY129224A (es)
NO (1) NO20030353L (es)
NZ (1) NZ523452A (es)
PA (1) PA8522801A1 (es)
PE (1) PE20020258A1 (es)
PL (1) PL366173A1 (es)
PT (1) PT1305319E (es)
RU (1) RU2276139C2 (es)
SI (1) SI1305319T1 (es)
TW (1) TWI287003B (es)
UY (1) UY26851A1 (es)
WO (1) WO2002008232A1 (es)
YU (1) YU2803A (es)
ZA (1) ZA200300219B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1103545B1 (en) * 1999-11-29 2003-11-05 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
TWI265807B (en) 2002-04-26 2006-11-11 Lilly Co Eli Tachykinin receptor antagonists
WO2003091227A1 (en) 2002-04-26 2003-11-06 Eli Lilly And Company Tachykinin receptor antagonists
AU2003300018A1 (en) * 2002-10-11 2004-05-04 Bristol-Myers Squibb Company Process for the preparation of tri-nitrogen containing heteroaryl-diamine derivatives useful as pharmaceutical agents and methods of producing pharmaceutical agents
EP1638944A1 (en) * 2003-06-12 2006-03-29 Eli Lilly And Company Tachykinin receptor antagonists
CA2530886C (en) * 2003-07-03 2013-05-28 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
US7288658B2 (en) * 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
CN1984891B (zh) 2004-07-06 2012-08-08 弗·哈夫曼-拉罗切有限公司 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
UA90708C2 (ru) 2005-02-25 2010-05-25 Ф. Хоффманн-Ля Рош Аг Таблетки с улучшенной дисперсностью лекарственного вещества
US8067662B2 (en) 2009-04-01 2011-11-29 Aalnex, Inc. Systems and methods for wound protection and exudate management
US7816577B2 (en) 2006-02-13 2010-10-19 Aalnex, Inc. Wound shield
KR101119365B1 (ko) 2006-05-31 2012-03-07 에프. 호프만-라 로슈 아게 아릴-4-에틴일-아이속사졸 유도체
WO2008090117A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
CN105745198B (zh) 2013-11-08 2018-09-21 橘生药品工业株式会社 羧甲基哌啶衍生物
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
US10538491B2 (en) 2015-03-16 2020-01-21 Vanderbilt University 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators
CN108712913B (zh) 2015-12-22 2022-06-24 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂
JP2021514976A (ja) 2018-02-26 2021-06-17 オスペダーレ・サン・ラッファエーレ・エッセエッレエッレ 眼痛の治療における使用のためのｎｋ−１拮抗薬

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
EP1462450B1 (en) 1993-12-29 2007-06-13 MERCK SHARP & DOHME LTD. Substituted morpholine derivatives and their use as therapeutic agents
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
KR20010041991A (ko) 1998-03-19 2001-05-25 다케다 야쿠힌 고교 가부시키가이샤 복소환식 화합물, 그의 제조법 및 타키키닌 수용체길항약으로서의 용도
PT1035115E (pt) * 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
HUP0200124A3 (en) * 1999-02-24 2004-03-01 Hoffmann La Roche Phenyl- and pyridinyl derivatives, process for their preparation and pharmaceutical compositions containing them
PT1157005E (pt) * 1999-02-24 2005-02-28 Hoffmann La Roche Derivados de 3-fenilpirina e a sua utilizacao como antagonistas do receptor nk-1
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
EP1103545B1 (en) * 1999-11-29 2003-11-05 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
ES2309075T3 (es) * 2000-07-14 2008-12-16 F. Hoffmann-La Roche Ag N-oxidos como profarmacos de derivados de 4-fenil-piridina antagonistas del receptor nk1.

Also Published As

Publication number Publication date
EP1305319A1 (en) 2003-05-02
CA2416874A1 (en) 2002-01-31
US20020038030A1 (en) 2002-03-28
CN1444589A (zh) 2003-09-24
IL153837A (en) 2008-06-05
US6576762B2 (en) 2003-06-10
ES2260265T3 (es) 2006-11-01
HUP0301272A2 (hu) 2003-08-28
AU2001282005B2 (en) 2006-10-19
PT1305319E (pt) 2006-08-31
ATE322496T1 (de) 2006-04-15
JO2321B1 (en) 2005-09-12
UY26851A1 (es) 2002-01-31
JP2004504400A (ja) 2004-02-12
SI1305319T1 (sl) 2006-08-31
DE60118569T2 (de) 2007-02-15
HK1058360A1 (en) 2004-05-14
ZA200300219B (en) 2004-04-08
PA8522801A1 (es) 2002-09-30
MXPA03000367A (es) 2003-05-27
BR0112695A (pt) 2003-04-22
CZ2003528A3 (cs) 2003-09-17
RU2276139C2 (ru) 2006-05-10
GT200100148A (es) 2002-05-16
NZ523452A (en) 2004-07-30
NO20030353D0 (no) 2003-01-23
TWI287003B (en) 2007-09-21
YU2803A (sh) 2006-01-16
NO20030353L (no) 2003-01-23
KR100527214B1 (ko) 2005-11-08
MY129224A (en) 2007-03-30
MA26933A1 (fr) 2004-12-20
AU8200501A (en) 2002-02-05
PE20020258A1 (es) 2002-04-02
US20030130508A1 (en) 2003-07-10
DE60118569D1 (de) 2006-05-18
CA2416874C (en) 2011-01-18
JP4118673B2 (ja) 2008-07-16
CY1106113T1 (el) 2011-06-08
DK1305319T3 (da) 2006-08-14
WO2002008232A1 (en) 2002-01-31
HU229231B1 (en) 2013-09-30
KR20030015898A (ko) 2003-02-25
HRP20030031A2 (en) 2004-02-29
EP1305319B1 (en) 2006-04-05
ECSP034446A (es) 2003-03-10
CN1192032C (zh) 2005-03-09
IL153837A0 (en) 2003-07-31
PL366173A1 (en) 2005-01-24
US6624176B2 (en) 2003-09-23

Similar Documents

Publication Publication Date Title
AR029875A1 (es) Derivados de 4-fenil-piridina
ATE411985T1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
UY26754A1 (es) Derivados de la 1, 3, 8, -triaza-spiro (4,5) decan-4-ona
SE0104332D0 (sv) Therapeutic agents
YU66101A (sh) Nova jedinjenja i kompozicije kao inhibitori proteaze
DK1263730T3 (da) Aminderivater til behandling af apoptose
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
HUP0302893A2 (hu) Nem-imidazol ariloxipiperidinek és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DE69927050D1 (de) Biphenylverbindungen und biphenyl-analoge als intergrin-antagonisten
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
NO20021448L (no) Nye tiazolo-(4,5-D)pyrimidinforbindelser
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
SE0403171D0 (sv) New compounds
BR0105563A (pt) Derivados e análogos de galantamina
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
SE0101322D0 (sv) Novel compounds
ATE505462T1 (de) Neue biologischaktive molekü le
DE60014394D1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
NO973857L (no) 1-aryl-2-acylamino-etanforbindelser og deres anvnedelse som neurokinin-, spesielt neurokinin-1-antagonister
NO308654B1 (no) Amid-derivater, fremgangsmÕter og mellomprodukter for fremstilling derav, deres anvendelse og farmasøytiske blandinger som inneholdende dem
SE0300445D0 (sv) New combination
PA8545601A1 (es) Derivados de 4-aminopirimidina
ATE372982T1 (de) 2-(3-sulfonylamino-2-oxopyrrolidin-1- yl)propanamide als factor xa inhibitoren

Legal Events

Date Code Title Description
FA Abandonment or withdrawal